Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX‐2)
- 23 March 2010
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 8 (4), 714-721
- https://doi.org/10.1111/j.1538-7836.2010.03748.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip ArthroplastyNew England Journal of Medicine, 2008
- Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialThe Lancet, 2007
- A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgeryJournal of Thrombosis and Haemostasis, 2007
- Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacementJournal of Thrombosis and Haemostasis, 2005
- Prevention of Venous ThromboembolismChest, 2004
- The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyJournal of Thrombosis and Haemostasis, 2003
- Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trialThe Lancet, 2002
- Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trialsThe Lancet, 2001
- Refining binomial confidence intervalsThe Canadian Journal of Statistics / La Revue Canadienne de Statistique, 1986
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972